The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or ...
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum Journal of Immunological MethodsWang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the ....
Demonstration of the phase lag increase of 5-layer nanoprobes functionalized by sHER2 antibodies on addition of sHER2 proteins (sHER2 assay). The nanoparticle concentration is 10 pM and the oscillating magnetic field amplitude is 5 mT. The binding sHER2 proteins are added twice. ...
The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or ...
Secondly, I demonstrate and characterize a first-in-kind microfluidic mobility shift assay for riboswitch screening applications. Riboswitches are RNA sequences that undergo a conformational change in response to binding by a regulatory small molecule ligand, resulting in modKarns, Kelly Melia...
The homogeneous mobility shift assay (HMSA) has many advantages over an ELISA for adalimumab monitoring but current HMSA methodologies do not discriminate between adalimumab and other TNF specific monoclonals such as infliximab. The development and validation of a competitive binding HMSA (cHMSA) ...
The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or ...
The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or ...
Sa1269 Improved Homogeneous Mobility Shift Assay (HMSA) for the Detection of Neutralizing Antibodies (NAB) in IBD Patients Treated With Infliximab or AdalimumabRecent studies have shown that TL1A (TNFSF15) is one of the definitive susceptibility genes to Crohn's disease (CD). To determine the ...
Official journal of the American College of Gastroenterology | ACGWang SL, Ohrmund L, Hauenstein S, et al. Evaluation of a novel homogeneous mobility shift assay for the measurement of human antibodies-To-Infliximab and infliximab levels in patient serum. Am J Gastroenterol 2011;106:S475-6....